McKesson's stock surged 5% in intraday trading, fueled by a combination of strong sector sentiment and company-specific positive developments. The rally mirrored broader gains in the healthcare distribution space after peer Cencora reported better-than-expected quarterly results and raised its annual profit forecast, citing robust demand for specialty and GLP-1 drugs.

Investors also reacted to a series of bullish catalysts for McKesson. Citigroup recently raised its price target on the stock to $1,000 while maintaining a Buy rating, and the company announced a 15% increase in its quarterly dividend, marking its 10th consecutive year of dividend growth. The upcoming fiscal 2027 first-quarter earnings release, scheduled after the bell, added to the positive momentum as analysts anticipate continued EPS growth.

Broader market commentary highlighted healthcare as an oversold and undervalued sector, with McKesson named as a top pick due to its reliable distribution business, high single-digit sales growth, and consistent share repurchases. The combination of industry tailwinds and company-specific execution drove the stock sharply higher.